generic of semaglutide Canada approves from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 patent The Scoop on Semaglutide :

Key limitations include poor bioavailability, rapid metabolism, and restricted penetration across the bloodnerve barrier

Semaglutide CVOT, SUSTAIN-6 Visual Abstract as a GIF In fact, Novo Nordisk used data like these to gain a new indication for semaglutide just last week: Today, the [FDA] approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight

Patients should be reassured that experiencing nausea does not indicate treatment failure, and with appropriate management strategies, most people can continue therapy successfully whilst symptoms gradually resolve

'